Chief Healthcare Executive July 6, 2024
This represents a new phase of data access, where hundreds of glucose reads per day per sensor provide greater insights into each patient’s disease management.
In an era shaped by the acceleration of healthcare technologies, the advent of over-the-counter (OTC) medical devices combines innovation with accessibility, symbolizing the availability of quality, equitable care.
Most recently, Continuous Glucose Monitoring (CGM) is poised to undergo a monumental shift following the March announcement of FDA clearance for Dexcom’s OTC Stelo Glucose Biosensor. More than just a regulatory milestone, this approval sends a message to the healthcare community about the growing opportunities for improvement in diabetes management.
Across the U.S. healthcare landscape, the approval of OTC CGM pushes consumer empowerment to new heights. The...
Today's Sponsors
Today's Sponsor